Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
May 31 2016 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael
Rogers, Chief Financial Officer, will present at the Goldman Sachs
Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT
(5:00pm ET).
A live audio webcast of the presentation can be accessed under
“Investor Events” in the Investor section of the Acorda website at
www.acorda.com, or you may use the link:
https://cc.talkpoint.com/gold006/060716b_ae/?entity=70_I1RTFEP
Please log in before the scheduled time of the presentations to
ensure a timely connection. An archived version of this webcast
will be available until July 7, 2016 on the Investors section of
www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda has an industry leading pipeline of novel neurological
therapies addressing a range of disorders, including Parkinson’s
disease, post-stroke walking difficulties, migraine, and multiple
sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to complete the Biotie
transaction on a timely basis; the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations and Civitas’ operations, respectively, into our
operations; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal
Spray, or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, Plumiaz, any other products under
development, or the products that we will acquire when we complete
the Biotie transaction; the occurrence of adverse safety events
with our products; delays in obtaining or failure to obtain and
maintain regulatory approval of or to successfully market Fampyra
outside of the U.S. and our dependence on our collaborator Biogen
in connection therewith; competition; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may
not actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and we disclaim
any intent or obligation to update any forward-looking statements
as a result of developments occurring after the date of this
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160531005010/en/
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024